United Therapeutics Corp
- Last sale
- Nov 12, 2026 · -0.34%
- Market cap
- $25.27B
- 42.59M shares
- Filings
- 1,223
Q3 2026+10.6% FY25 yoy
Q3 2026+11.7% FY25 yoy
Q3 2026+8.4% FY25 yoy
Q3 2026derived−3.7% FY25 yoy
Q3 2026+13.1% FY25 yoy
Q3 2026−8.3% FY25 yoy
- $25.27B
- 20.5×
- 7.9×
- 4.0×
- 3.43%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3,182,700,000 | reported | |
| FY 2024 | 2024-12-31 | $2,877,400,000 | reported | |
| FY 2023 | 2023-12-31 | $2,327,500,000 | reported | |
| FY 2022 | 2022-12-31 | $1,936,300,000 | reported | |
| FY 2021 | 2021-12-31 | $1,685,500,000 | reported | |
| FY 2020 | 2020-12-31 | $1,483,300,000 | reported | |
| FY 2019 | 2019-12-31 | $1,448,800,000 | reported | |
| FY 2018 | 2018-12-31 | $1,627,800,000 | reported | |
| FY 2017 | 2017-12-31 | $1,725,300,000 | reported | |
| FY 2016 | 2016-12-31 | $1,598,800,000 | reported | |
| FY 2015 | 2015-12-31 | $1,465,800,000 | reported | |
| FY 2014 | 2014-12-31 | $1,288,500,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $1.00B | $1.00B | — | 43.83M sh | −2.4% | 96.1% |
| FY2024 | — | $1.00B | $1.00B | — | 44.91M sh | −4.6% | 92.5% |
| FY2023 | — | $0.00 | $0.00 | — | 47.06M sh | +1.6% | 0.0% |
| FY2022 | — | $0.00 | $0.00 | — | 46.30M sh | +2.6% | 0.0% |
| FY2017 | — | $250.00M | $250.00M | — | 43.24M sh | −3.8% | 64.4% |
Segments
LineFY2025ShareChange
United States$3.04B95%+10.9%
Rest-of-World$145.70M4.6%+5.8%
Total$3.18B
Pharmaceutical preparations
United Therapeutics Corp is the 24th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4BPRGOPerrigo Co PLC$4.3B2.8%33.5%$2.2BGMABGenmab A/S$3.7B19.2%25.9%—ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BBMRNBioMarin Pharmaceutical Inc$3.2B12.9%10.8%$11.0B
UTHRUnited Therapeutics Corp (this company)$3.2B10.6%41.9%$25.3B
AMRXAmneal Pharmaceuticals, Inc.$3.0B8.0%2.4%$7.5BRPRXRoyalty Pharma plc$2.4B5.1%32.4%$39.6BSRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
United Therapeutics Corp · CIK 1082554 · Engraved from SEC EDGAR